Beiersdorf
This article was originally published in The Rose Sheet
Executive Summary
Skin care brands Onagrine and Nobacter acquired from Boots for $28.6 mil. (FF1=$.13). Purchases represent Beiersdorf's foray into French pharmaceutical skin care market, German company says. Onagrine and Nobacter products will continue to be manufactured by Boots in Chace, France while 27 employees in product development, marketing and sales will transition to Beiersdorf. Firm has no plans to expand brand distribution outside France, Beiersdorf says. Boots, which acquired brands in 1990s to achieve critical mass in French skin care market, will record loss of $12.7 mil. ([L]1=$1.41) for sale, UK retailer/marketer says. Core skin care focus has moved to dermatitis and acne since firm acquired Clearasil from Procter & Gamble last year for $340 mil. (1"The Rose Sheet" Oct. 23, 2000, p. 3)
You may also be interested in...
Boots Healthcare Gains Access To U.S. Market Through Clearasil Buy
Boots Healthcare International views its acquisition of the Clearasil acne prevention and treatment brand as a possible springboard for creating an OTC drug marketing presence in the U.S.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle